Liam Ratcliffe
QuietNamed in filings at New LeafOn the current fund
- Board seats filed
- 8
- Named on a board
- 0
all filings on record
Named in filings at New LeafOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Halda Therapeutics | Biotech & pharma | December 2021 | Vida Ventures |
| Eliem Therapeutics | Biotech & pharma | October 2020 | None on file |
| CuraSen Therapeutics | Biotech & pharma | September 2018 | Longitude Capital |
| Aptinyx | Biotech & pharma | May 2016 | Bain Capital Life Sciences, Longitude Capital |
| ARVINAS HOLDING COMPANY | Biotech & pharma | October 2015 | 270 Healthcare Growth |
| Afferent Pharmaceuticals | Biotech & pharma | July 2015 | None on file |
| Unum Therapeutics | Biotech & pharma | June 2015 | Atlas Venture |
| Neuronetics | Medical devices | November 2014 | Atlas Venture |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Liam Ratcliffe on the board, based on 8 filed seats with a verified or cited source.